Welcome to our dedicated page for Medicus Pharma news (Ticker: MDCX), a resource for investors and traders seeking the latest updates and insights on Medicus Pharma stock.
Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech and life sciences company whose news flow centers on clinical trial progress, regulatory milestones, strategic collaborations and capital markets activity. The company describes itself as a precision guided biotech/life sciences organization focused on advancing SkinJect™, an investigational microneedle therapy for basal cell carcinoma (BCC) of the skin, and Teverelix, a long-acting GnRH antagonist for hormone-driven conditions.
News updates frequently cover the SkinJect™ program, including Phase 2 study SKNJCT-003 in the United States, regulatory and ethics approvals to expand into the United Kingdom, and SKNJCT-004 in the United Arab Emirates. Releases also highlight interactions with the U.S. Food and Drug Administration (FDA), such as Type C meeting feedback supporting a 505(b)(2) regulatory pathway and the filing of an FDA Commissioner’s National Priority Voucher (CNPV) application for SKNJCT-003.
Another major theme in MDCX news is the Teverelix pipeline, added through the acquisition of Antev Limited. Company communications describe prior Phase 1 and Phase 2a data, FDA guidance on Phase 3 design, and plans to use AI-enabled analytics—via an engagement with Reliant AI Inc.—to support upcoming Teverelix clinical studies. Additional coverage includes Phase 1 data in healthy female volunteers and acceptance of Teverelix research for presentation at a leading endocrinology conference.
Investors following MDCX news will also see announcements on collaborations, such as the Gorlin Syndrome Alliance partnership for compassionate access to SkinJect™ and a non-binding memorandum of understanding with Helix Nanotechnologies, Inc. around thermostable infectious disease vaccines. Capital markets updates, including warrant inducement agreements, standby equity purchase activity and debenture financings, are disclosed through press releases and Form 8-K filings.
This news page aggregates these developments so readers can review Medicus Pharma’s clinical, regulatory, partnering and financing announcements in one place.
Medicus Pharma (NASDAQ:MDCX) will host a live fireside chat on March 19, 2026 to review positive Phase 2 SkinJect (SKNJCT-003) topline results.
Key data: 73% clinical clearance in the 200-µg D-MNA arm at Day 57 versus 38% in the device-only P-MNA control, supporting further development and regulatory discussions.
Medicus Pharma (NASDAQ: MDCX) announced that Dr. Babar K. Rao will provide clinical interpretation of positive Phase 2 SkinJect (SKNJCT-003) topline data during a business webcast on March 26, 2026. The randomized, double-blind study showed 73% clinical clearance in the 200-µg D-MNA arm vs 38% in the device-only arm at Day 57, with 40% histological clearance in the active cohort. Management views the dataset as decision-grade evidence to pursue regulatory discussions and potential strategic partnerships.
Medicus Pharma (NASDAQ:MDCX) announced that Dr. Raza Bokhari, Executive Chairman & CEO, will participate in the Longwood Miami CEO Forum on March 11-13, 2026 at the Ritz-Carlton Key Biscayne. He will join a panel titled "Accelerating the Path to Patient Care" to discuss the company's AI-enabled drug development strategy.
The invitation-only event gathers life sciences leaders for panels, fireside chats, and roundtables; notable participants include senior leaders from Pfizer, GSK, Editas, and others.
Medicus Pharma (NASDAQ: MDCX) reported Phase 2 SKNJCT-003 topline results for SkinJect: the 200-µg cohort achieved 73% clinical clearance and 40% histological clearance at Day 57, versus 38% clinical clearance in the P-MNA arm. The company calls the dataset decision-grade and plans an End-of-Phase-2 meeting with the FDA and to pursue partnering discussions.
Medicus also noted UK regulatory approvals to expand SKNJCT-003, completed U.S. enrollment of 90 patients, and recent corporate development activities including an August 2025 MoU and acquisitions.
Medicus Pharma (NASDAQ: MDCX) reported Phase 2 SKNJCT-003 topline results showing the 200µg D-MNA cohort reached 73% clinical clearance and 40% histological clearance (CR) at Day 57. The randomized, placebo-controlled study enrolled 90 patients; final CSR is expected in Q2 2026 to support an end-of-Phase-2 meeting with the FDA.
Results improved from Day 29 to Day 57, the company says the dataset is decision-grade for partnering discussions but notes the study was not powered for registrational endpoints.
Medicus Pharma (NASDAQ: MDCX) announced participation in the 38th Annual Roth Conference March 22-24, 2026, with a Fireside Chat by Executive Chairman & CEO Dr. Raza Bokhari on March 24, 2026, 12:30pm PT. Topics include SkinJect in Gorlin Syndrome, AI-enabled drug development, Teverelix progress, partnering readiness, and one-on-one investor meetings.
Medicus Pharma (NASDAQ:MDCX) CEO Dr Raza Bokhari was interviewed on Bloomberg World on February 10, 2026, outlining the company's AI-driven drug development strategy and near-term clinical catalysts.
Management disclosed nearly $14 million of personal capital committed at $4 per share and highlighted a planned Phase 2 Skinject data readout in H1 2026 as a potential value catalyst.
Medicus Pharma (NASDAQ: MDCX) received FDA "study may proceed" clearance to start a Phase 2b dose-optimization study of Teverelix in 40 men with advanced prostate cancer and high cardiovascular risk. The open-label trial tests a 540 mg loading regimen and six-week 360 mg maintenance doses through Day 155, targeting >90% castration probability. Company also highlights Phase 2a historical data, parallel SkinJect Phase 2 enrollment of 90 patients with topline data expected Q1 2026, and prior regulatory alignments to support a Phase 3 pathway and differentiated CV-focused labeling.
Medicus Pharma (NASDAQ:MDCX) celebrated its one-year Nasdaq listing with an Opening Bell ceremony on January 23, 2026. The company said it has advanced its clinical portfolio toward Phase 2 proof-of-concept studies while pursuing licensing and strategic partnerships.
Medicus highlighted two lead programs: SkinJect for basal cell carcinoma with an estimated market opportunity of $2 billion, and Teverelix for advanced prostate cancer. The company reported the Teverelix royalty rate on worldwide net sales was reduced from ~4% to 2%, and the royalty term was clarified on a country-by-country basis to improve partner attractiveness. Management emphasized disciplined execution and ongoing business development efforts.
Medicus Pharma (NASDAQ: MDCX) amended its LifeArc license for Teverelix, reducing the royalty rate from ~4% to 2% while preserving exclusive worldwide rights, sublicensing ability, IP ownership of Medicus-developed improvements, and operational control.
The release cites a ~$6 billion potential combined market for AURr and high cardiovascular‑risk prostate cancer. Parallel updates: SkinJect Phase 2 enrollment completed with 90 patients and topline data expected in Q1 2026, with an end-of-Phase 2 FDA meeting planned in H1 2026.